Richard J. Bonnie

Richard J. Bonnie

Auto-generated profile, based on publicly available information

Richard J. Bonnie

University of Virginia School of Law, Charlottesville

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Journal of Law, Medicine & Ethics
Verified
Journal Article
Open access
JCJames F. Childress
James F. Childress
RFRuth R. Faden
Ruth R. Faden
RGRuth D. Gaare
Ruth D. Gaare
LGLawrence O. Gostin
Lawrence O. Gostin
JKJeffrey Kahn
Jeffrey Kahn
PNPhillip Nieburg
Phillip Nieburg
Public health ethics, like the field of public health it addresses, traditionally has focused more on practice and particular cases than on theory, with the result that some concepts, methods, and boundaries remain largely undefined. This paper attempts to provide a rough conceptual map of the terrain of public health ethics. We begin by briefly defining public health and identifying general features of the field that are particularly relevant for a discussion of public health ethics.Public health is primarily concerned with the health of the entire population, rather than the health of individuals. Its features include an emphasis on the promotion of health and the prevention of disease and disability; the collection and use of epidemiological data, population surveillance, and other forms of empirical quantitative assessment; a recognition of the multidimensional nature of the determinants of health; and a focus on the complex interactions of many factors—biological, behavioral, social, and environmental—in developing effective interventions.

31 March 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JLJoshua D. Lee
Joshua D. Lee
PFPeter D. Friedmann
Peter D. Friedmann
TKTimothy W. Kinlock
Timothy W. Kinlock
ENEdward V. Nunes
Edward V. Nunes
TBTamara Y. Boney
Tamara Y. Boney
COCharles P. O’bRien
Charles P. O’bRien
Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited. In this five-site, open-label, randomized trial, we compared a 24-week course of extended-release naltrexone (Vivitrol) with usual treatment, consisting of brief counseling and referrals for community treatment programs, for the prevention of opioid relapse among adult criminal justice offenders (i.e., persons involved in the U.S. criminal justice system) who had a history of opioid dependence and a preference for opioid-free rather than opioid maintenance treatments and who were abstinent from opioids at the time of randomization. The primary outcome was the time to an opioid-relapse event, which was defined as 10 or more days of opioid use in a 28-day period as assessed by self-report or by testing of urine samples obtained every 2 weeks; a positive or missing sample was computed as 5 days of opioid use. Post-treatment follow-up occurred at weeks 27, 52, and 78. A total of 153 participants were assigned to extended-release naltrexone and 155 to usual treatment. During the 24-week treatment phase, participants assigned to extended-release naltrexone had a longer median time to relapse than did those assigned to usual treatment (10.5 vs. 5.0 weeks, P<0.001; hazard ratio, 0.49; 95% confidence interval [CI], 0.36 to 0.68), a lower rate of relapse (43% vs. 64% of participants, P<0.001; odds ratio, 0.43; 95% CI, 0.28 to 0.65), and a higher rate of opioid-negative urine samples (74% vs. 56%, P<0.001; odds ratio, 2.30; 95% CI, 1.48 to 3.54). At week 78 (approximately 1 year after the end of the treatment phase), rates of opioid-negative urine samples were equal (46% in each group, P=0.91). The rates of other prespecified secondary outcome measures — self-reported cocaine, alcohol, and intravenous drug use, unsafe sex, and reincarceration — were not significantly lower with extended-release naltrexone than with usual treatment. Over the total 78 weeks observed, there were no overdose events in the extended-release naltrexone group and seven in the usual-treatment group (P=0.02). In this trial involving criminal justice offenders, extended-release naltrexone was associated with a rate of opioid relapse that was lower than that with usual treatment. Opioid-use prevention effects waned after treatment discontinuation. (Funded by the National Institute on Drug Abuse; ClinicalTrials.gov number, NCT00781898.)

24 February 2016 in Psychological Science
Verified
Journal Article
Closed access
ACAlexandra O. Cohen
Alexandra O. Cohen
KBKaitlyn Breiner
Kaitlyn Breiner
LSLaurence Steinberg
Laurence Steinberg
RBRichard J. Bonnie
Richard J. Bonnie
ESElizabeth S. Scott
Elizabeth S. Scott
BCB. J. Casey
B. J. Casey
An individual is typically considered an adult at age 18, although the age of adulthood varies for different legal and social policies. A key question is how cognitive capacities relevant to these policies change with development. The current study used an emotional go/no-go paradigm and functional neuroimaging to assess cognitive control under sustained states of negative and positive arousal in a community sample of one hundred ten 13- to 25-year-olds from New York City and Los Angeles. The results showed diminished cognitive performance under brief and prolonged negative emotional arousal in 18- to 21-year-olds relative to adults over 21. This reduction in performance was paralleled by decreased activity in fronto-parietal circuitry, implicated in cognitive control, and increased sustained activity in the ventromedial prefrontal cortex, involved in emotional processes. The findings suggest a developmental shift in cognitive capacity in emotional situations that coincides with dynamic changes in prefrontal circuitry. These findings may inform age-related social policies.

1 June 1992 in Behavioral Sciences & the Law
Verified
Journal Article
Closed access
PDF file
RBRichard J. Bonnie
Richard J. Bonnie

27 October 2009 in Neurology
Verified
Journal Article
Closed access
PDF file
DLDan Larriviere
Dan Larriviere
MWMichael A. Williams
Michael A. Williams
MRMatt Rizzo
Matt Rizzo
RBRichard J. Bonnie
Richard J. Bonnie
In the last decade, persons who have no diagnosed medical or mental health condition are increasingly seeking and utilizing, for the ostensible purpose of enhancing their memory or cognitive skills, prescription drugs that were originally developed to improve executive function or memory in persons diagnosed with disorders such as attention deficit hyperactivity disorder or Alzheimer disease. Evidence suggests that this practice, now known as neuroenhancement, is gathering momentum. As a result, neurologists may be encountering patients without a diagnosed illness asking for medications with the goal of improving their memory, cognitive focus, or attention span. Strong arguments have been made for and against this practice, often reflecting strongly held convictions concerning the appropriate practice of medicine. The purpose of this report is to provide neurologists with an overview of the ethical, legal, and social issues surrounding the use of pharmaceuticals prescribed to enhance or augment normal cognitive or affective functioning, as well as practical guidance for responding to an adult patient’s request for neuroenhancement.

1 September 2001 in Psychiatric Services
Verified
Journal Article
Closed access
JMJohn Monahan
John Monahan
RBRichard J. Bonnie
Richard J. Bonnie
PAPaul S. Appelbaum
Paul S. Appelbaum
PHPamela S. Hyde
Pamela S. Hyde
HSHenry J. Steadman
Henry J. Steadman
MSMarvin S. Swartz
Marvin S. Swartz